ADEROLIO

Brand name authorized in: Austria Poland

Active ingredients

The drug ADEROLIO contains one active pharmaceutical ingredient (API):

1 Everolimus
UNII 9HW64Q8G6G - EVEROLIMUS

Everolimus is a selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine-threonine kinase, the activity of which is known to be upregulated in a number of human cancers.

Read about Everolimus

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Everolimus
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA18

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
PL
Rejestru Produktów Leczniczych
Identifier(s): 100401859, 100401865, 100401871, 100401888